logo Hematology/Oncology Research Studies: Open for Enrollment Date: 10/22/18

Category: SICKLE CELL DISEASE

Efficacy and Safety of Rivipansel in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

NCT#/Phase: NCT02187003
Phase 3
IRB#: 2016-104
Description: This multicenter, randomized, double-blind, placebo-controlled study evaluates the efficacy and safety of rivipansel (GMI-1070) in the treatment of vaso-occlusive crisis in hospitalized subjects with sickle cell disease.
Inclusion: Individuals who are 6 years of age or older who have HbSS, HbSC, or HbS/Beta-0 thalassemia and are diagnosed with a VOC at time of admission to the hospital.
Enrollment Status: Open for enrollment
Sponsor: Pfizer
Principal Investigator(s): Lynne Neumayr, MD
Contact(s): Kacie Smith (510-428-3885 x2752)
Mariam Hameed (510 428-3885 x4151)
Sheila Contapay-Tabilin, RN (510 428-3885 x4754)
Study Link: https://clinicaltrials.gov/ct2/show/NCT02187003

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000